Processing

Please wait...

Settings

Settings

1. WO2000040595 - ANTISENSE MODULATION OF NOVEL ANTI-APOPTOTIC BCL-2-RELATED PROTEINS

Publication Number WO/2000/040595
Publication Date 13.07.2000
International Application No. PCT/US1999/029593
International Filing Date 14.12.1999
Chapter 2 Demand Filed 31.07.2000
IPC
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
CPC
C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N 15/1135
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1135against oncogenes or tumor suppressor genes
C12N 2310/315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
315Phosphorothioates
C12N 2310/318
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
318where the PO2 is completely replaced, e.g. MMI or formacetal
C12N 2310/3181
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
318where the PO2 is completely replaced, e.g. MMI or formacetal
3181Peptide nucleic acid, PNA
C12N 2310/321
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
32of the sugar
3212'-O-R Modification
Applicants
  • ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue Carlsbad, CA 92008, US (AllExceptUS)
  • ACKERMANN, Elizabeth, J. [US/US]; US (UsOnly)
  • BENNETT, C., Frank [US/US]; US (UsOnly)
  • DEAN, Nicholas, M. [GB/US]; US (UsOnly)
  • MARCUSSON, Eric, G. [US/US]; US (UsOnly)
Inventors
  • ACKERMANN, Elizabeth, J.; US
  • BENNETT, C., Frank; US
  • DEAN, Nicholas, M.; US
  • MARCUSSON, Eric, G.; US
Agents
  • LICATA, Jane, Massey ; Law Offices of Jane Massey Licata 66 E. Main Street Marlton, NJ 08053, US
Priority Data
09/226,56807.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTISENSE MODULATION OF NOVEL ANTI-APOPTOTIC BCL-2-RELATED PROTEINS
(FR) MODULATION ANTISENS DE PROTEINES ANTI-APOPTOSE PROCHES DE BCL-2
Abstract
(EN)
Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic blc-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.
(FR)
L'invention concerne des compositions et des techniques qui permettent de moduler l'expression de nouvelles protéines anti-apoptose proches de bcl-2. Les composés préférés sont des oligonucléotides antisens A1 et mcl-1 qui ciblent des acides nucléiques codant pour des protéines anti-apoptose proches de bcl-2. L'invention concerne également des méthodes qui permettent d'utiliser ces composés pour moduler l'expression des protéines anti-apoptose proches de bcl-2 et pour traiter les maladies associées à l'expression desdites protéines; ainsi que des méthodes qui permettent d'utiliser ces composés pour induire l'apoptose et traiter les maladies dans lesquelles on désire induire l'apoptose.
Latest bibliographic data on file with the International Bureau